ArticleStem cell reviews and reports2017
Magnetic Resonance Imaging of Ferumoxytol-Labeled Human Mesenchymal Stem Cells in the Mouse Brain.
Article in Stem cell reviews and reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 29 citations in OpenAlex.
- SPIONs-labeled hUCMSCs for in vitro safety analysis and in vivo tracking in scarred monkey uteri.Scientific reports · 2026Article
- Future direction: molecular imaging-based stem cell research.European journal of nuclear medicine and molecular imaging · 2025Article
- Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials.Nanoscale advances · 2024Review
- IntraBrain Injector (IBI): A Stereotactic-Guided Device for Repeated Delivery of Therapeutic Agents Into the Brain Parenchyma.Journal of Korean medical science · 2022Article
- MRI tracking of human Wharton's jelly stem cells seeded onto acellular dermal matrix labeled with superparamagnetic iron oxide nanoparticles in burn wounds.Burns & trauma · 2022Article
- Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle.Theranostics · 2022Review
- Iron Oxide Nanoparticles in Regenerative Medicine and Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2021Review
- Biodistribution of Mesenchymal Stromal Cells after Administration in Animal Models and Humans: A Systematic Review.Journal of clinical medicine · 2021Review
- Cellular and molecular imaging for stem cell tracking in neurological diseases.Stroke and vascular neurology · 2021Review
- Personalized-induced neural stem cell therapy: Generation, transplant, and safety in a large animal model.Bioengineering & translational medicine · 2021Article
- NoninvasiveWorld journal of stem cells · 2020Review
- Mesenchymal stem cells as a multimodal treatment for nervous system diseases.Stem cells translational medicine · 2020Review
- Exploring the Potential of Mesenchymal Stem Cell-Based Therapy in Mouse Models of Vascular Cognitive Impairment.International journal of molecular sciences · 2020Article
- Heterogeneous Disease Progression in a Mouse Model of Vascular Cognitive Impairment.International journal of molecular sciences · 2020Article
- MRI-Tracking of Dental Pulp Stem Cells In Vitro and In Vivo Using Dextran-Coated Superparamagnetic Iron Oxide Nanoparticles.Journal of clinical medicine · 2019Article
- Homing and Tracking of Iron Oxide Labelled Mesenchymal Stem Cells After Infusion in Traumatic Brain Injury Mice: a Longitudinal In Vivo MRI Study.Stem cell reviews and reports · 2018Article
- Stem Cell Tracing Through MR Molecular Imaging.Tissue engineering and regenerative medicine · 2018Review
- Imaging Gliomas with Nanoparticle-Labeled Stem Cells.Chinese medical journal · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The success of stem cell therapy is highly dependent on accurate delivery of stem cells to the target site of interest. Possible ways to track the distribution of MSCs in vivo include the use of reporter genes or nanoparticles. The U.S. Food and Drug Administration (FDA) has approved ferumoxytol (Feraheme® [USA], Rienso® [UK]) as a treatment for iron deficiency anemia. Ferumoxytol is an ultrasmall superparamagnetic iron oxide nanoparticle (USPIO) that has recently been used to track the fate of transplanted cells using magnetic resonance imaging (MRI). The major objectives of this study were to demonstrate the feasibility of labeling hUCB-MSCs with ferumoxytol and to observe, through MRI, the engraftment of ferumoxytol-labeled human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) delivered via stereotactic injection into the hippocampi of a transgenic mouse model of familial Alzheimer's disease (5XFAD). Ferumoxytol had no toxic effects on the viability or stemness of hUCB-MSCs when assessed in vitro. Through MRI, hypointense signals were discernible at the site where ferumoxytol-labeled human MSCs were injected. Iron-positive areas were also observed in the engrafted hippocampi. The results from this study support the use of nanoparticle labeling to monitor transplanted MSCs in real time as a follow-up for AD stem cell therapy in the clinical field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.